ClinicalTrials.gg
RecruitingNCT06535659Updated Oct 1, 2026

VitaFlow LIBERTY Europe

An observational study in Aortic Valve Stenosis, sponsored by Shanghai MicroPort CardioFlow Medtech Co., Ltd.. Recruiting at 9 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Shanghai MicroPort CardioFlow Medtech Co., Ltd. (part of MicroPort Scientific Corporation) · Observational

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.
Updated Oct 1, 2026First site in PortugalSite recruiting status changed+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
222
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 118 studies in Aortic Valve Stenosis with a site in Italy — 39 open to participants now, 54 under way, 1 of them phase 3. Aortic Valve Stenosis · Italy.

Planned enrollment
55th of 71
222 · median 500
Started
2025
with 9 others
Observational
71 of 118
21 open now
Primary completion
2028-06
later than 43 of 53 live
Registered
100th of 118
by date

Among the 118 studies in Aortic Valve Stenosis with a site in Italy, this one is the 55th largest by planned enrollment of the 71 observational ones that give a count, is one of 10 that started in 2025, is one of 71 observational ones, reaches primary completion later than 43 of the 53 other live ones, and was the 100th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

39 of the 118 studies in Aortic Valve Stenosis with a site in Italy are open now. Recruiting first, the newest first:

33 more — sign in →

All 39 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 118 studies in Aortic Valve Stenosis with a site in Italy, or all of them as a file.
02

Study summary

This is a prospective, single-arm, multi-center, observational, post-market clinical investigation to document the clinical safety and performance of MicroPort CardioFlow VitaFlow Liberty™ Transcatheter Aortic Valve System in the routine practice for the treatment of severe aortic valve stenosis. The primary endpoint is the composite rate of all-cause mortality and stroke with disability at 12 months.

Patients will receive transcatheter aortic valve replacement and examinations at the screening, procedure, discharge, and follow-up per local standard of care.

03

Conditions studied

  • Aortic Valve Stenosis

Keywords

  • Transcatheter aortic valve replacement
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with symptomatic, severe calcified aortic stenosis who are at high surgical risk.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects of age≥ 18 years
  2. Subjects with severe, symptomatic, calcific aortic stenosis who are considered at high risk for surgical aortic valve replacement (AVR).
  3. Subject can understand the purpose of the clinical investigation, has signed voluntarily the form and is agreeing to the scheduled follow up requirements.

Exclusion criteria

Exclusion Criteria:

  1. Pre-existing mechanical heart valve in aortic position
  2. A known or to all anticoagulation /antiplatelet regimens (or inability to be anticoagulated for the index procedure), to nickel or titanium, to nitinol, to dairy products, to polyethylene terephthalate (PET) or contrast media
  3. Ongoing sepsis, including active endocarditis
  4. Anatomically not suitable for the VitaFlow Liberty TAV system
  5. \<20%
  6. Estimated of less than 12 months
  7. Any medical, social or psychological condition that in the opinion of the Heart Team precludes the subject from receiving transcatheter aortic valve replacement
  8. Currently participating in another drug or device trial (excluding registries) for which the primary endpoint has not been assessed
  9. Inability to comply with the clinical investigation follow-up or other clinical investigation requirements
  10. Patients temporally unable to provide written (e. g. unconscious emergency patients)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
222 participants (estimated)
Patient registry
No

Groups and cohorts

  • Single arm clinical investigation

    Device: VitaFlow Liberty™ Transcatheter Aortic Valve System

Interventions

  • DeviceVitaFlow Liberty™ Transcatheter Aortic Valve System

    Transcatheter Aortic Valve Replacement with VitaFlow Liberty™ Transcatheter Aortic Valve System. Patients will receive transcatheter aortic valve replacement and examinations at the screening, procedure, discharge, and follow-up per local standard of care.

06

What researchers measure

Primary outcomes

  1. Composite rate of all-cause mortality and stroke with disability

    Composite rate of all-cause mortality and stroke with disability

    Time frame: 12 months post procedure

Secondary outcomes

  1. Safety outcomes defined by VARC3

    Rate of all-cause mortality, myocardial infarction, stroke, implanted related new and/or worsen conduction disturbances and arrhythmias, new permanent pacemaker implantation, procedure-related or valve-related hospitalization defined by VARC 3.

    Time frame: 30 days, 12 months, and 2-5 years post procedure

  2. Safety outcomes defined by VARC3

    Rate of type 2-4 bleeding, major vascular and access-related complications, acute kidney injury (stage 2-4) defined by VARC 3

    Time frame: 30 days and 12 months post procedure

  3. Safety outcomes defined by VARC3

    Rate of other acute procedural and technical valve related complications: conversion to surgery; unplanned use of mechanical circulatory support; implantation of multiple (\>1) transcatheter valves during the index hospitalization; valve mal-position

    Time frame: acute procedure (within 24 hours)

  4. Device success

    Device success defined by VARC 3

    Time frame: 30 days post implantation

  5. Device early safety

    Device early safety defined by VARC 3

    Time frame: 30 days post implantation

  6. Bioprosthesis haemodynamic function

    Bioprosthesis haemodynamic function (assessed by echocardiography) including effective orifice area (cm2).

    Time frame: Discharge (24 hours to 7 days), 30 days,12 months and 2-5 years post implantation

  7. Bioprosthesis haemodynamic function

    Bioprosthesis haemodynamic function (assessed by echocardiography) including mean transvalvular gradient (mmHg).

    Time frame: Discharge (24 hours to 7 days), 30 days,12 months and 2-5 years post implantation

  8. Bioprosthesis haemodynamic function

    Bioprosthesis haemodynamic function (assessed by echocardiography) including aortic regurgitation (paravalvular, central and total).

    Time frame: Discharge (24 hours to 7 days), 30 days,12 months and 2-5 years post implantation

  9. Bioprosthetic valve dysfunction

    Moderate or severe haemodynamic valve deterioration defined by VARC3

    Time frame: 12 months and 2-5 years post procedure

  10. Bioprosthetic valve dysfunction

    Bioprosthetic valve failure defined by VARC3

    Time frame: 12 months and 2-5 years post procedure

  11. Bioprosthetic valve dysfunction

    Clinically significant valve thrombosis defined by VARC3

    Time frame: 12 months and 2-5 years post procedure

  12. NYHA Classification

    Changes in cardiac function at discharge, 30 days and 12 months and 2-5 years post implantation according to the NYHA Classification Scheme compared to baseline

    Time frame: From baseline to discharge (24 hours to 7 days), 30 days, 12 months and 2-5 years post procedure

  13. Rate of Alwide Plus Balloon Catheter pre-dilation success

    Defined as successful access, delivery and dilation the aortic valve, and retrieval for the AlwideTM Plus balloon catheter

    Time frame: During procedure

  14. Alwide Plus Balloon Catheter related adverse-event

    Time frame: Discharge

  15. Predictors for the permanent pacemaker implantation

    Including but not limited to pre-existing conduction disturbance, implant depth, LVOT calcium volume , post-dilatation

    Time frame: Baseline or intraprocedure

07

Study locations

9 of 9 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Jun 2028, 37 months after the start.

Of 37 industry-sponsored observational studies under Aortic Valve Stenosis, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 47. This study's planned 37 months is close to that.

Counting every sponsor, half of 243 studies reached it within 44 months; a quarter within 23 and three quarters within 86.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: primary completion Jun 2027 → Jun 2028 and completion Jun 2032 → Jun 2033.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2024
First posted
Aug 2, 2024
StartActual
May 6, 2025
Primary completionEst.
Jun 6, 2028was Jun 2027
CompletionEst.
Jun 2033was Jun 2032
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added — first site in Portugal. Galway University Hospital is now Recruiting
Show 3 added (2 Italy, 1 Portugal)
  • Pineta Grande Hospital · Castel Volturno, Italy
  • Azienda Ospedaliera Regionale -S.Carlo · Potenza, Italy
  • Hospital de Santa Cruz · Carnaxide, Portugal
Oct 1, 2026
Primary completion
Jun 6, 2027→Jun 6, 2028
Oct 1, 2026
Study completion
Jun 2032→Jun 2033
Oct 1, 2026
Enrollment
122→222
Oct 1, 2026
Secondary outcomes
3 added
What changed in the outcomes
  • AddedRate of Alwide Plus Balloon Catheter pre-dilation successTime frame: During procedure
  • AddedAlwide Plus Balloon Catheter related adverse-eventTime frame: Discharge
  • AddedPredictors for the permanent pacemaker implantationTime frame: Baseline or intraprocedure
Oct 1, 2026
Contact
Study contact changed: l•••@microport.com · •••3642→Y•••@cf.microport.com · •••3409. See the current contact
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    3 sites added — first site in Portugal. Galway University Hospital is now Recruiting
    Show 3 added (2 Italy, 1 Portugal)
    • Pineta Grande Hospital · Castel Volturno, Italy
    • Azienda Ospedaliera Regionale -S.Carlo · Potenza, Italy
    • Hospital de Santa Cruz · Carnaxide, Portugal
    Primary completion Jun 6, 2027→Jun 6, 2028
    Study completion Jun 2032→Jun 2033
    Enrollment 122→222
    Secondary outcomes 3 added
    What changed in the outcomes
    • AddedRate of Alwide Plus Balloon Catheter pre-dilation successTime frame: During procedure
    • AddedAlwide Plus Balloon Catheter related adverse-eventTime frame: Discharge
    • AddedPredictors for the permanent pacemaker implantationTime frame: Baseline or intraprocedure
    Contact Study contact changed: l•••@microport.com · •••3642→Y•••@cf.microport.com · •••3409. See the current contact
    + 1 other change: description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06535659
Responsible party
Sponsor
First posted
Aug 2, 2024
Start date
May 6, 2025
Primary completion
Jun 6, 2028 (estimated)
Completion
Jun 2033 (estimated)
Last update
Oct 1, 2026

Study contacts

Yann Poezevara, PhD
Contact
Yann.Poezevara@cf.microport.com
0033-146013409
Zhujun Cai, PhD
Contact
zjcai@microport.com
86-021-38954600
Darren Mylotte, MD
principal investigator · Galway University Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion